Adicet Bio, Inc. 8-K

What Happened Adicet Bio, Inc. (ACET) filed an 8-K reporting that its Board approved and the company effected a 1-for-16 reverse stock split of its common stock. The Board approved the split on December 19, 2025, the certificate of amendment was filed December 26, 2025, and the reverse split became effective at 12:01 a.m. Eastern Time on December 30, 2025. Trading on The Nasdaq Capital Market will begin on a split-adjusted basis at market open on December 30, 2025 under the existing ticker "ACET."

Key Details

• Reverse split ratio: 1-for-16 (every 16 pre-split shares became 1 post-split share).
• Effective times/dates: Board approval December 19, 2025; amendment filed December 26, 2025; effective 12:01 a.m. ET on December 30, 2025.
• Fractional shares: No fractional post-split shares will be issued; holders entitled to fractional shares will receive cash in lieu.
• Corporate effects: Authorized shares and par value unchanged; proportional adjustments made to equity incentive plan awards, outstanding options, convertible securities and warrants. New CUSIP: 007002207.
• Public disclosure: Company issued a press release (filed as Exhibit 99.1) and included the certificate of amendment as Exhibit 3.1 in the 8-K.

Why It Matters The reverse stock split reduces the number of outstanding shares and increases the per-share price on a mathematical basis only; it does not change the company’s market value, authorized share count, or the par value per share. Investors should note the adjustments to equity awards, options and warrants, and that fractional-share holders will receive cash payments instead of fractional shares. Trading will reflect the adjusted share count and price starting Dec 30, 2025. For risks and forward-looking information, see Adicet’s SEC filings referenced in the 8-K.